Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × DLBCL × acalabrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9 Lymphoma, Mantle-Cell 5 Lymphoma, Non-Hodgkin 4 Lymphoma 3 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Leukemia 2 Waldenstrom Macroglobulinemia 1 Multiple Myeloma 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Hairy Cell 1 Leukemia, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Glioblastoma 1 DLBCL 1 Burkitt Lymphoma 1

Interventions

vistusertib 1 acalabrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Acerta Pharma BV

Phase 1/2 Terminated

25 enrolled 11 charts

DLBCL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡